Biomaterial Database

[The inhalational glucocorticosteroid Inhacort in the treatment of bronchial asthma: the efficacy of long-term therapy]. 1998

Iu A Tereshchenko, and L N Tislenko, and E I Vanetik

OBJECTIVE The study of efficacy and safety of ingacort in severe and moderate asthma. METHODS Clinical response to ingacort, frequency of its recurrences, hospitalizations, duration of hospital stay were assessed on the treatment month 12, 24 and 36 in 58, 30 and 11 patients with bronchial asthma (BA), respectively. RESULTS 12 months of ingacort treatment promoted a decline in BA symptoms: day and night episodes became less frequent, requirement of beta-2-agonists decreased, bronchial obstruction regressed. Doses of systemic steroids were reduced twice or discontinued. Asthmatic statuses occurred 10 times less frequently. This effect persisted throughout the following 2 years. Side effects were registered within the first year of the treatment and emerged after local use of the drug. CONCLUSIONS Long-term administration of ingacort in bronchial asthma is safe and effective.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D011446	Prospective Studies	Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.	Prospective Study,Studies, Prospective,Study, Prospective
D002908	Chronic Disease	Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260	Female		Females
D005446	Fluocinolone Acetonide	A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)	Fluortriamcinolone Acetonide,Alvadermo,Capex,Co-Fluocin,Cortiespec,Derma-Smooth FS,Flucinar,Fluocid,Fluodermo,Fluonid,Fluotrex,Flurosyn,Flusolgen,Gelidina,Jellin,Jellisoft,Synalar,Synalar-HP,Synamol,Synemol,Acetonide, Fluocinolone,Acetonide, Fluortriamcinolone,Co Fluocin,Derma Smooth FS,Synalar HP
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280	Administration, Inhalation	The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.	Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000293	Adolescent	A person 13 to 18 years of age.	Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults